Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence

Table 3 Predictors of recurrence stratified according to recurrence time by Log-rank test

Variable	Recurrence, P value
	Overall	Early	Late
Men	0.726	0.768	0.848
Age ≥ 62 yr	0.080	0.006	0.530
HBV	0.143	0.046	0.875
Cirrhosis	0.259	0.134	0.957
Ascites	0.022	0.219	0.028
ALT ≥ 44 U/L	0.086	0.118	0.429
AST ≥ 55 U/L	< 0.001	0.005	0.001
ALP ≥ 116 U/L	< 0.001	0.011	0.001
GGT ≥ 144 U/L	< 0.001	0.004	0.007
PLT ≥ 148 × 109/L	0.021	0.376	0.009
PT (INR) ≥ 1.17	0.398	0.390	0.792
AFP ≥ 96 ng/mL	0.003	0.005	0.246
AFP ≥ 200 ng/mL	0.008	0.011	0.316
Tumor size ≥ 5 cm	< 0.001	< 0.001	0.001
Multiple tumors	0.125	0.169	0.471
Vascular invasion	0.063	0.205	0.150
CLIP ≥ 1	< 0.001	0.001	0.116
CLIP ≥ 2	< 0.001	< 0.001	0.386
Positive Pohl	0.748	0.683	0.993
Positive AARP	0.181	0.120	0.861
AAR ≥ 1.07	0.048	0.491	0.021
API ≥ 6	0.771	0.402	0.575
CDS ≥ 8	0.678	0.972	0.466
APRI ≥ 1.94	0.022	0.053	0.213
APRI ≥ 0.56	0.080	0.054	0.665
FIB-4 ≥ 4.3	0.044	0.130	0.152
FibroQ ≥ 6.36	0.025	0.131	0.084
Lok ≥ 0.33	0.836	0.698	0.870
Lok ≥ 0.70	0.078	0.592	0.026
GUCI ≥ 2.24	0.050	0.318	0.050
GUCI ≥ 0.65	0.125	0.088	0.757
APGA ≥ 26.9	< 0.001	< 0.001	0.333
PAPAS ≥ 2.41	< 0.001	0.002	0.034
PAPAS ≥ 3.62	< 0.001	0.001	0.024

AAR: Aspartate aminotransferase/alanine aminotransferase ratio; AARP: AAR-platelet count score; AFP: Alpha-fetoprotein; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; APGA: Aspartate aminotransferase/platelet count/γ-glutamyl transpeptidase/AFP index; API: Age/platelet count index; APRI: Aspartate aminotransferase/platelet count ratio index; AST: Aspartate aminotransferase; CDS: Cirrhosis discriminant score; CLIP: Cancer of the Liver Italian Program; FIB-4: Fibrosis index based on the four factors; FibroQ: Fibro-quotient; GGT: γ-glutamyl transpeptidase; GUCI: Goteburg University Cirrhosis Index; HBV: Hepatitis B virus; INR: International normalized ratio; PAPAS: Platelet count/age/ALP/AFP/AST index; PLT: Platelet count; PT: Prothrombin time.